IOVA news

Iovance reported a 24.6% objective response rate in non-squamous mNSCLC, enabling a planned sBLA in 2027 and initiation of a precision TIL strategy for evaluating specific biomarker subgroups.

Iovance Biotherapeutics, Inc. filed an exhibit including a corporate overview presentation and forward-looking statements regarding its product commercialization and development plans. This highlights the company’s strategic positioning for future growth.

Iovance raised full-year 2026 revenue expectations to $410-$420 million due to strong U.S. demand for Amtagvi and Proleukin, marking a notable increase over the previous forecast.

Iovance Biotherapeutics Inc. filed a regulatory exhibit outlining a corporate overview and forward-looking statements, which includes risk factors and details regarding commercial product development. Sentiment remains neutral as this is a standard informational filing.

Iovance Biotherapeutics posted record second-quarter revenue of ~$99 million and raised gross margins, while updating investors to expect a review of its full-year revenue guidance.

Iovance Biotherapeutics, Inc. filed an 8-K exhibit (99.1) containing a corporate overview. The document includes standard forward-looking statements regarding risks related to commercialization, manufacturing, and future financial results.

Iovance Biotherapeutics announced that Australia's TGA approved Amtagvi (lifileucel) for previously treated advanced melanoma, marking the company's third marketing authorization for the therapy. This approval addresses a significant market need in Australia, which has the highest melanoma incidence…